Sandra L Beretta, MD
Obstetrics/Gynecology · Oakland
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 4 carriers
- Office
- 1
- Since medical school
- 38 years
- University of Southern California Keck School of Medicine, 1988
Offices
1 location · UCSF Health Medical Foundation · 65 clinicians in this group
Hospitals listed: Mills-Peninsula Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 4 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Beretta’s office at (510) 428-3000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$16,828
Medicare paid this office $16,828 for 109 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 70 | $6,271 | $73 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 80 | $3,789 | $47 |
| Return visit (30+ min) | 18 | $2,378 | $108 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $738 | $57 |
Procedures Medicare counted
| Skin biopsy | 1-10 | None |
Who their Medicare patients are
109 Original Medicare patients in 2024. Average age 74 · Women 100% · Also on Medicaid 0% · Health risk score 0.67. At or below the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 50% · Cancer 15% · Atrial fibrillation 12% · Depression 12% · Coronary heart disease 11%.
The office billed $68,656, Medicare allowed $21,937 and paid $16,828; for 211 services of 13 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 109 | 211 | 74 | 0.67 | $68,656 | $16,828 |
| 2023 | 117 | 247 | 74 | 0.68 | $79,926 | $16,930 |
| 2022 | 93 | 143 | 74 | 0.64 | $43,275 | $10,615 |
| 2021 | 99 | 161 | 74 | 0.61 | $39,520 | $11,150 |
| 2020 | 68 | 109 | 74 | 0.76 | $36,393 | $7,660 |
| 2019 | 99 | 165 | 74 | 0.71 | $56,917 | $12,157 |
| 2018 | 86 | 125 | 74 | 0.72 | $22,933 | $8,557 |
| 2017 | 109 | 184 | 73 | 0.66 | $25,697 | $13,246 |
| 2016 | 140 | 218 | 73 | 0.69 | $34,775 | $14,065 |
| 2015 | 88 | 112 | 73 | 0.63 | $17,262 | $8,581 |
| 2014 | 74 | 118 | 73 | 0.56 | $11,573 | $8,022 |
| 2013 | 95 | 158 | 71 | 0.61 | $17,105 | $11,977 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 4 services
| Short return visit (20+ min) | 80 | $7,595 | $67 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 79 | $3,704 | $47 |
| Return visit (30+ min) | 18 | $1,920 | $101 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 13 | $711 | $55 |
2022: 3 services
| Short return visit (20+ min) | 46 | $3,782 | $68 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 49 | $2,275 | $46 |
| Return visit (30+ min) | 17 | $1,979 | $94 |
2021: 3 services
| Short return visit (20+ min) | 39 | $3,603 | $74 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 75 | $3,531 | $47 |
| Return visit (30+ min) | 13 | $1,799 | $120 |
2020: 4 services
| Short return visit (20+ min) | 31 | $2,109 | $57 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 33 | $1,556 | $47 |
| Return visit (30+ min) | 18 | $1,016 | $56 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 12 | $642 | $53 |
2019: 4 services
| Return visit (30+ min) | 33 | $3,271 | $91 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 55 | $2,525 | $46 |
| Short return visit (20+ min) | 29 | $2,338 | $62 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 14 | $742 | $53 |
2018: 3 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 60 | $2,615 | $44 |
| Return visit (30+ min) | 20 | $2,298 | $92 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 17 | $897 | $53 |
2017: 3 services
| Return visit (30+ min) | 31 | $3,072 | $81 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 50 | $2,581 | $52 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 60 | $2,558 | $43 |
2016: 4 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 89 | $3,905 | $44 |
| Return visit (30+ min) | 29 | $2,549 | $85 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 46 | $2,474 | $54 |
| Short return visit (20+ min) | 15 | $1,138 | $63 |
2015: 2 services
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 58 | $2,457 | $42 |
| Return visit (30+ min) | 19 | $1,789 | $89 |
2014: 3 services
| Return visit (30+ min) | 33 | $3,143 | $85 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 38 | $1,633 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 28 | $1,467 | $52 |
2013: 3 services
| Return visit (30+ min) | 45 | $4,266 | $84 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 48 | $2,079 | $43 |
| Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | 38 | $2,057 | $54 |
Drugs they prescribed that Part D paid
$20,090
Pharmacies billed $20,090 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
217 generic and 25 brand-name prescriptions · $20,090 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Estradiol | 98 | $6,104 | $62 |
| Estradiol-Norethindrone Acetat | 26 | $2,164 | $83 |
| Estradiol (Twice Weekly) | 12 | $1,267 | $106 |
| Progesterone | 21 | $815 | $39 |
| Valacyclovir | 14 | $642 | $46 |
See all 6 drugs
| Estradiol | 98 | $6,104 | $62 |
| Estradiol-Norethindrone Acetat | 26 | $2,164 | $83 |
| Estradiol (Twice Weekly) | 12 | $1,267 | $106 |
| Progesterone | 21 | $815 | $39 |
| Valacyclovir | 14 | $642 | $46 |
| Fluconazole | 20 | $322 | $16 |
Year by year
| 2024 | 242 | 73 | None | 10% | $20,090 |
| 2023 | 207 | 73 | None | 24% | $32,993 |
| 2022 | 187 | 59 | None | 25% | $28,332 |
| 2021 | 173 | 57 | 0% (0) | 21% | $26,387 |
| 2020 | 203 | 60 | None | 24% | $34,140 |
| 2019 | 217 | 60 | 0% (0) | 29% | $37,984 |
| 2018 | 188 | 60 | None | 36% | $31,289 |
| 2017 | 212 | 69 | None | 37% | $31,314 |
| 2016 | 201 | 63 | 0% (0) | 47% | $32,771 |
| 2015 | 136 | 46 | None | 60% | $24,530 |
| 2014 | 135 | 40 | None | 51% | $16,241 |
| 2013 | 180 | 47 | None | 57% | $20,330 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 5 drugs
| Premarin | 24 | $11,990 | $500 |
| Estradiol | 61 | $9,750 | $160 |
| Estradiol-Norethindrone Acetat | 15 | $1,446 | $96 |
| Estradiol (Twice Weekly) | 13 | $1,106 | $85 |
| Progesterone | 13 | $606 | $47 |
2022: 4 drugs
| Premarin | 29 | $12,273 | $423 |
| Estradiol | 54 | $6,709 | $124 |
| Acyclovir | 11 | $1,001 | $91 |
| Progesterone | 14 | $430 | $31 |
2021: 2 drugs
| Premarin | 30 | $12,965 | $432 |
| Estradiol | 66 | $7,151 | $108 |
2020: 4 drugs
| Estradiol | 70 | $11,296 | $161 |
| Premarin | 26 | $10,085 | $388 |
| Yuvafem | 12 | $2,614 | $218 |
| Valacyclovir | 24 | $642 | $27 |
2019: 3 drugs
| Premarin | 30 | $12,533 | $418 |
| Estradiol | 70 | $11,184 | $160 |
| Valacyclovir | 26 | $656 | $25 |
2018: 6 drugs
| Premarin | 31 | $12,816 | $413 |
| Estrace | 16 | $4,996 | $312 |
| Estradiol | 38 | $4,524 | $119 |
| Prempro | 14 | $3,153 | $225 |
| Yuvafem | 11 | $2,178 | $198 |
| Valacyclovir | 21 | $410 | $20 |
2017: 6 drugs
| Premarin | 35 | $10,697 | $306 |
| Yuvafem | 15 | $4,421 | $295 |
| Estrace | 12 | $3,455 | $288 |
| Estradiol | 40 | $2,847 | $71 |
| Valacyclovir | 11 | $397 | $36 |
| Medroxyprogesterone Acetate | 17 | $334 | $20 |
2016: 7 drugs
| Premarin | 37 | $8,977 | $243 |
| Vagifem | 17 | $6,336 | $373 |
| Estrace | 23 | $5,924 | $258 |
| Combipatch | 11 | $2,991 | $272 |
| Estradiol | 25 | $2,024 | $81 |
| Medroxyprogesterone Acetate | 14 | $245 | $17 |
| Fluconazole | 12 | $142 | $12 |
2015: 2 drugs
| Vagifem | 27 | $7,515 | $278 |
| Premarin | 26 | $6,714 | $258 |
2014: 6 drugs
| Premarin | 18 | $4,431 | $246 |
| Vagifem | 20 | $2,927 | $146 |
| Estrace | 13 | $1,938 | $149 |
| Climara | 13 | $1,290 | $99 |
| Medroxyprogesterone Acetate | 14 | $187 | $13 |
| Estradiol | 15 | $133 | $9 |
2013: 7 drugs
| Premarin | 21 | $4,203 | $200 |
| Prempro | 15 | $1,947 | $130 |
| Estrace | 17 | $1,883 | $111 |
| Vagifem | 13 | $1,443 | $111 |
| Climara | 14 | $1,318 | $94 |
| Medroxyprogesterone Acetate | 20 | $176 | $9 |
| Estradiol | 15 | $137 | $9 |
Money from drug and device companies
$202 in 2025
| 2025 | 8 | 10 | None | $202 |
| 2024 | 3 | 7 | None | $126 |
| 2023 | 5 | 7 | None | $141 |
| 2022 | 2 | 4 | None | $87 |
| 2021 | 3 | 11 | None | $226 |
| 2020 | 5 | 7 | None | $131 |
| 2019 | 6 | 9 | None | $191 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Astellas Pharma US | Veozah | $59 | 2 payments
|
| CooperSurgical | Paragard T 380a | $39 | 2 payments
|
| Exact Sciences | Cologuard Collection Kit | $24 | 1 payment
|
| Hologic Sales and Service | Novasure | $20 | 1 payment
|
| Mayne Pharma Commercial | None | $19 | 1 payment
|
| Biogen | Zurzuvae | $17 | 1 payment
|
See all 10 published payments
| CooperSurgical | Meals · 2025-12-12 | Paragard T 380a | $20 |
| Meditrina | Meals · 2025-10-28 | None | $9 |
| Exact Sciences | Meals · 2025-10-01 | Cologuard Collection Kit | $24 |
| Minerva Surgical | Meals · 2025-07-31 | None | $14 |
| Biogen | Meals · 2025-07-01 | Zurzuvae | $17 |
| Mayne Pharma Commercial | Meals · 2025-04-08 | None | $19 |
| Astellas Pharma US | Meals · 2025-03-05 | Veozah | $28 |
| Astellas Pharma US | Meals · 2025-02-05 | Veozah | $31 |
| CooperSurgical | Meals · 2025-01-29 | Paragard T 380a | $19 |
| Hologic Sales and Service | Meals · 2025-01-09 | Novasure | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $126
| Mayne Pharma Commercial | None | $88 | 5 payments
|
| Aspira Women's Health | Ova1 | $21 | 1 payment
|
| Pfizer | Paxlovid | $18 | 1 payment
|
2023: $141
| Mayne Pharma Commercial | None | $52 | 3 payments
|
| AbbVie | Orilissa | $26 | 1 payment
|
| Hologic Sales and Service | Aptima | $25 | 1 payment
|
| CooperSurgical | Paragard T 380a | $19 | 1 payment
|
| Exact Sciences | Cologuard Collection Kit | $19 | 1 payment
|
2022: $87
| Abbvie | Liletta | $66 | 3 payments
|
| TherapeuticsMD | Annovera | $21 | 1 payment
|
2021: $226
| AbbVie | Lo Loestrin Fe | $160 | 8 payments
|
| TherapeuticsMD | Annovera | $47 | 2 payments
|
| Daiichi Sankyo | Injectafer | $19 | 1 payment
|
2020: $131
| AbbVie | Lo Loestrin Fe | $43 | 2 payments
|
| Pfizer | Premarin | $40 | 2 payments
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $19 | 1 payment
|
| CooperSurgical | Paragard | $16 | 1 payment
|
| Avion Pharmaceuticals | Balcoltra | $14 | 1 payment
|
2019: $191
| AbbVie | Orilissa | $81 | 4 payments
|
| CooperSurgical | Paragard | $28 | 1 payment
|
| Roche Diagnostics | Rs Harmony Test Related Products | $25 | 1 payment
|
| Pfizer | Premarin | $20 | 1 payment
|
| Daiichi Sankyo | Injectafer | $20 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Kyleena | $18 | 1 payment
|
Professional record
- NPI
- 1568573889
- Licence
- CA G068308
- Trained
- University of Southern California Keck School of Medicine, 1988 · 38 years ago
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 136 N San Mateo Dr Ste 101, San Mateo, CA, 94401
- NPI first listed
- 2006-08-31
- NPI last updated
- 2017-01-18
This is when the NPI record was last certified, not a medical board exam.